Clinical Research Study

 
News Articles for Clinical Research Study top ^
Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform BARCELONA , Nov.
Sign-up for Trovagene Releases Clinical Study Results for the Detection and Monitoring of KRAS Mutations in Circulating Tumor DNA of Colorectal Cancer Patients investment picks
2014/11/20
Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome Canada NewsWire TORONTO , Nov.
Sign-up for Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome investment picks
Prospective blinded study demonstrates ability to accurately determine mutational status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA SAN DIEGO , Oct.
Sign-up for Clinical Study Using Trovagene's Precision Cancer Monitoring Platform Published in Cancer Discovery investment picks
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain.
Sign-up for AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress investment picks
MIAMI , October 9, 2014 /PRNewswire/ -- Technology Applications International Corporation (OTCBB: NUUU) (the "Company" or "NUUU") announced today that they a concluded a clinical study to test the efficacy of their products at Essex Testing Clinic in Verona, NJ .
Sign-up for NUUU Announces the Results of a Clinical Study that Tested the Efficacy of its Wholly Owned Subsidiary's Rejuvel Line of Anti-Aging Products that use NASA* Patented Technology investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65 th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting ® .
Sign-up for Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively.
Sign-up for Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in Antimicrobial Agents and Chemotherapy investment picks
Orthofix International N.V., (NASDAQ:OFIX), today announced the Company’s first large-scale clinical study to evaluate the use of pulsed electromagnetic fields (PEMF) technology to see if the therapy can improve osteogenesis (bone growth) in Type II odontoid fractures.
Sign-up for Orthofix Initiates First US Clinical Study of Osteogenesis Stimulation for Odontoid Fractures investment picks
2014/11/19
Results of two clinical studies of the LuViva® Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods.
Sign-up for Nigerian Clinical Studies Demonstrate Advantages of LuViva® Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa investment picks
NBI-98854 TO BE EVALUATED FOR BOTH CHILDREN AND ADOLESCENTS IN T-FORCE CLINICAL TRIAL SAN DIEGO , Oct.
Sign-up for Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study investment picks
VLU STUDY PATIENTS TREATED WITH EPIFIX® ALLOGRAFT HAD DOUBLE THE RATE OF WOUND CLOSURE COMPARED TO CONTROL GROUP MARIETTA, Ga.
Sign-up for MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147572&ProfileId=051205&sourceType=1 AURORA, ON --
Sign-up for Helix BioPharma Corp. Initiates Enrollment for Tenth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in a Phase IIa clinical study evaluating whether its investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide symptomatic relief to patients with diabetic gastroparesis.
Sign-up for Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology (EAU) 14 th Central European Meeting in Cracow, Poland (10-12 October 2014). The primary objective of the study was to assess the efficacy and safety profile of the sustained-release triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer.
Sign-up for Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients investment picks
2014/11/20
TORONTO , Nov.
Sign-up for Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome investment picks
Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Programs  |  Next: Clinical Results